Canexia Health, a Canadian cancer genomic program, has announced a new partnership with Project ACTT (Access to Cancer Testing & Treatment in Response to COVID-19), thus increasing the speed of cancer testing for targeted treatment "during the pandemic through a minimally invasive circulating tumor DNA test...as an alternative to some surgical tissue biopsies for patients with advanced lung, breast, or colorectal cancer."
Since launching in July 2020, more than 800 Canadian cancer patients have been tested via Project ACTT, with the program expanding to Nova Scotia, New Brunswick, Quebec, Ontario, Saskatchewan, Alberta, and British Columbia. Further, 11% of samples received are from rural and remote areas where patients did not have access to urban academic research hospitals.
To read more about this program, click here.
No comments:
Post a Comment